Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T22:03:14.258Z.
Consensus retrieved: unavailable. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T22:03:14.258Z.
Quote observation: 2026-10-05T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 0fde8dae4c5ae63ee7b35c7e6e46bba2fdf5d6d5db310b32cf0eb41a7e17e840
FORWARD PE RATIO
N/A
MiniMed Group, Inc.
Market Cap
$560.00M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| MiniMed Group, Inc. (MMEDV) | $560.00M | N/A |
| CytomX Therapeutics, Inc. (CTMX)vs › | $557.32M | N/A |
| CorMedix Inc. (CRMD)vs › | $571.13M | 14.71 |
| Phathom Pharmaceuticals, Inc. (PHAT)vs › | $548.51M | N/A |
| Aquestive Therapeutics, Inc. (AQST)vs › | $578.40M | N/A |
| ProKidney Corp. (PROK)vs › | $538.01M | N/A |
| OrthoPediatrics Corp. (KIDS)vs › | $583.31M | N/A |
| Fulgent Genetics, Inc. (FLGT)vs › | $584.48M | N/A |
| Monopar Therapeutics Inc. (MNPR)vs › | $533.04M | N/A |
| Delcath Systems, Inc. (DCTH)vs › | $531.98M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus fiscal-year EPS
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
